LOW-DOSE METHOTREXATE AND DOXORUBICIN IN HORMONE-RESISTANT PROSTATIC-CANCER

被引：3
|
作者：
SMITH, MF
LAWSON, AH
KIRK, D
KAYE, SB
机构：
[1] Department of Urology, Law Hospital, Carluke
来源：
BRITISH JOURNAL OF UROLOGY | 1990年 / 65卷 / 05期
关键词：
D O I：
10.1111/j.1464-410X.1990.tb14798.x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Summary— A group of 24 patients, all of whom had progressive disease following initial hormone therapy for advanced prostatic carcinoma, were given intravenous methotrexate (30 mg/m2) and doxorubicin (15 mg/m2) at 2‐week intervals for a planned 6‐treatment course. Seventeen patients completed the full course. Assessment included “quality of life” criteria, using the subjective assessment of performance status, severity of pain and analgesic consumption. Over half of the patients improved in each of these modalities and 8 (33%) improved in all 3. As toxicity was acceptable, low dose chemotherapy may have a part to play in these patients who present a difficult management problem. © 1990 British Journal of Urology
引用
收藏
页码：513 / 516
页数：4
相关论文
共 50 条
  • [31] Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer
    Scheusan, R.
    Curescu, S.
    Stanculeanu, D.
    Curescu, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] THE NON-HORMONE CHEMOTHERAPY OF PROSTATIC-CANCER
    JONES, MA
    WILLIAMS, G
    BRITISH JOURNAL OF UROLOGY, 1980, 52 (02): : 127 - 130
  • [33] mTOR inhibition in hormone-resistant breast cancer
    Sharma, Sharan Prakash
    LANCET ONCOLOGY, 2012, 13 (06): : E239 - E239
  • [34] Capecitabine in hormone-resistant metastatic prostatic carcinoma – a phase II trial
    R Morant
    J Bernhard
    D Dietrich
    S Gillessen
    M Bonomo
    M Borner
    J Bauer
    T Cerny
    C Rochlitz
    M Wernli
    A Gschwend
    S Hanselmann
    F Hering
    H-P Schmid
    British Journal of Cancer, 2004, 90 : 1312 - 1317
  • [35] RESISTANCE TO HORMONE-THERAPY IN PROSTATIC-CANCER
    PAVONE, C
    SERRETTA, V
    INGARGIOLA, GB
    DARICELLO, G
    CARAMIA, G
    PAVONEMACALUSO, M
    RESISTANCE TO ANTITUMOR AGENTS: LABORATORY AND CLINICAL STUDIES, 1989, 7 : 163 - 182
  • [36] Low-dose methotrexate toxicity
    Pivovarov, Kevin
    Zipursky, Jonathan S.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (15) : E423 - E423
  • [37] New findings for hormone-resistant prostate cancer
    Kerr, C
    LANCET ONCOLOGY, 2006, 7 (04): : 292 - 292
  • [38] IS LOW-DOSE METHOTREXATE NEPHROTOXIC
    MARCE, S
    BANNWARTH, B
    SCHAEVERBEKE, T
    DEHAIS, J
    JOURNAL OF RHEUMATOLOGY, 1993, 20 (10) : 1806 - 1807
  • [39] Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial
    Morant, R
    Bernhard, J
    Dietrich, D
    Gillessen, S
    Bonomo, M
    Borner, M
    Bauer, J
    Cerny, T
    Rochlitz, C
    Wernli, M
    Gschwend, A
    Hanselmann, S
    Hering, F
    Schmid, HP
    BRITISH JOURNAL OF CANCER, 2004, 90 (07) : 1312 - 1317
  • [40] Challenges and Opportunities in Hormone-Resistant Prostate Cancer
    Miller, Kurt
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (01) : 36 - 45
12345